|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
JP6313712B2
(ja)
*
|
2011-12-21 |
2018-04-18 |
アムジエン・インコーポレーテツド |
新生児Ｆｃ受容体への結合を強化された変異型Ｆｃポリペプチド
|
|
KR102211837B1
(ko)
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
JO3519B1
(ar)
*
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
UY36245A
(es)
*
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
EP3174901B1
(en)
|
2014-07-31 |
2019-06-26 |
Amgen Research (Munich) GmbH |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
CA2963696A1
(en)
*
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
|
|
PT3221356T
(pt)
*
|
2014-11-20 |
2020-10-29 |
Hoffmann La Roche |
Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
|
|
DK3221357T3
(da)
*
|
2014-11-20 |
2020-08-10 |
Hoffmann La Roche |
Fælles letkæder og fremgangsmåder til anvendelse
|
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
ES2744540T3
(es)
*
|
2014-12-05 |
2020-02-25 |
Hoffmann La Roche |
Anticuerpos anti-CD79b y procedimientos de uso
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
AU2015364396B2
(en)
*
|
2014-12-19 |
2018-08-09 |
Alkermes, Inc. |
Single chain Fc fusion proteins
|
|
CN120988137A
(zh)
|
2015-01-23 |
2025-11-21 |
赛诺菲 |
抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
|
|
EP3253790A4
(en)
|
2015-02-06 |
2018-07-25 |
University of Maryland, Baltimore |
Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
|
|
CN107750255B
(zh)
|
2015-04-17 |
2022-08-30 |
安进研发（慕尼黑）股份有限公司 |
用于cdh3和cd3的双特异性抗体构建体
|
|
US9708412B2
(en)
*
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
US10738118B2
(en)
*
|
2015-05-29 |
2020-08-11 |
Amphivena Therapeutics, Inc. |
Methods of using bispecific CD33 and CD3 binding proteins
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
FR3038517B1
(fr)
*
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
IL313507A
(en)
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
EA201891753A1
(ru)
*
|
2016-02-03 |
2019-01-31 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
|
|
GB201604458D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against cancers
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
WO2017162587A1
(en)
*
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
JOP20170091B1
(ar)
*
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
EP3493844A4
(en)
|
2016-05-20 |
2021-03-24 |
Harpoon Therapeutics Inc. |
SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
WO2017201493A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
WO2018005226A2
(en)
|
2016-06-22 |
2018-01-04 |
Alkermes, Inc. |
Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
|
|
CN109715663B
(zh)
|
2016-06-28 |
2022-11-25 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
|
AU2017363300A1
(en)
|
2016-11-23 |
2019-06-20 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
WO2018098356A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
|
SMT202500367T1
(it)
|
2017-02-02 |
2025-11-10 |
Amgen Res Munich Gmbh |
Composizione farmaceutica a basso ph comprendente costrutti di anticorpo che reclutano le cellule t
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
UY37726A
(es)
|
2017-05-05 |
2018-11-30 |
Amgen Inc |
Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
|
|
EP3621994A4
(en)
|
2017-05-12 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
MESOTHELIN BINDING PROTEINS
|
|
WO2018209304A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
MX2020003915A
(es)
|
2017-10-13 |
2020-10-08 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso.
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
EP3694885A1
(en)
|
2017-10-14 |
2020-08-19 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
AU2018383679B2
(en)
|
2017-12-11 |
2025-10-09 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
|
AU2018387829B2
(en)
|
2017-12-22 |
2024-12-19 |
Argenx Bvba |
Bispecific antigen binding construct
|
|
CN109957026A
(zh)
*
|
2017-12-22 |
2019-07-02 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
CN108610417B
(zh)
*
|
2018-04-28 |
2021-01-26 |
暨南大学 |
抗破伤风毒素中和抗体、其制备方法及用途
|
|
BR112020023330A2
(pt)
|
2018-05-14 |
2021-04-20 |
Harpoon Therapeutics, Inc. |
porção de ligação para ativação condicional de moléculas de imunoglobulina
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
PT3820569T
(pt)
|
2018-07-12 |
2025-01-14 |
Invox Pharma Ltd |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
ES3044118T3
(en)
|
2018-07-12 |
2025-11-26 |
Invox Pharma Ltd |
Antibody molecules that bind cd137 and ox40
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
CA3107186A1
(en)
|
2018-07-30 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
|
CA3105729A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Dosing regimen for bcma-cd3 bispecific antibodies
|
|
WO2020025792A1
(en)
|
2018-08-03 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Antibody constructs for cldn18.2 and cd3
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
MA53732A
(fr)
|
2018-09-28 |
2022-01-05 |
Amgen Inc |
Anticorps dirigés contre bcma soluble
|
|
JP7644706B2
(ja)
|
2018-10-11 |
2025-03-12 |
アムジエン・インコーポレーテツド |
二重特異性抗体コンストラクトの下流プロセシング
|
|
MX2021004510A
(es)
|
2018-10-23 |
2021-06-08 |
Amgen Inc |
Calibracion automatica y mantenimiento automatico de modelos espectroscopicos de raman para predicciones en tiempo real.
|
|
AU2019412561A1
(en)
*
|
2018-12-24 |
2021-08-12 |
Sanofi |
Multispecific binding proteins with mutant Fab domains
|
|
TWI871300B
(zh)
|
2019-01-28 |
2025-02-01 |
美商安進公司 |
藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
|
|
US11840575B2
(en)
|
2019-05-07 |
2023-12-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Engineered immune cells targeting BCMA and their uses thereof
|
|
AU2020275002A1
(en)
|
2019-05-14 |
2021-12-23 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
|
CN116987197A
(zh)
*
|
2019-06-20 |
2023-11-03 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
|
US20210032370A1
(en)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Recruiting agent further binding an mhc molecule
|
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
|
US20220306741A1
(en)
|
2019-09-10 |
2022-09-29 |
Amgen Inc. |
Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
|
|
WO2021091906A1
(en)
|
2019-11-04 |
2021-05-14 |
Amgen Inc. |
Methods for treating leukemia
|
|
LT3819007T
(lt)
|
2019-11-11 |
2024-10-10 |
Amgen Research (Munich) Gmbh |
Dozavimo režimas, skirtas anti-bcma agentams
|
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
|
FI4065585T3
(fi)
|
2019-11-25 |
2025-09-26 |
Alkermes Inc |
Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
|
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
|
EP4090365A1
(en)
|
2020-01-15 |
2022-11-23 |
Immatics Biotechnologies GmbH |
Antigen binding proteins specifically binding prame
|
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
WO2021158469A1
(en)
|
2020-02-03 |
2021-08-12 |
Amgen Inc. |
Multivariate bracketing approach for sterile filter validation
|
|
TWI888487B
(zh)
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與ｃｄ３結合之雙特異性抗體
|
|
CN115768463A
(zh)
|
2020-02-21 |
2023-03-07 |
哈普恩治疗公司 |
Flt3结合蛋白及使用方法
|
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
|
WO2021188851A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
WO2021231969A1
(en)
*
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
|
US20240209085A1
(en)
|
2020-05-29 |
2024-06-27 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
|
|
WO2021255155A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cd19
|
|
CN116322763A
(zh)
|
2020-08-27 |
2023-06-23 |
学校法人顺天堂 |
抗切断型突变calr-cd3双特异性抗体及医药组合物
|
|
MX2023003041A
(es)
|
2020-09-16 |
2023-05-09 |
Amgen Inc |
Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
|
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
|
WO2022096704A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
|
UY39507A
(es)
|
2020-11-06 |
2022-03-31 |
Amgen Res Munich Gmbh |
Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
|
|
CR20230229A
(es)
|
2020-11-06 |
2023-09-05 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
|
TW202225188A
(zh)
|
2020-11-06 |
2022-07-01 |
德商安美基研究（慕尼黑）公司 |
與ｃｄ３結合的多肽構建體
|
|
EP4243936A1
(en)
|
2020-11-10 |
2023-09-20 |
Amgen Inc. |
Methods for administering a bcma x cd3 binding molecule
|
|
US20250277024A1
(en)
*
|
2020-12-03 |
2025-09-04 |
Amgen Inc. |
Molecules with multiple binding domains
|
|
US11760747B2
(en)
|
2020-12-21 |
2023-09-19 |
Alkermes, Inc. |
Substituted piperidino compounds and related methods of treatment
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
JP2024509877A
(ja)
|
2021-03-10 |
2024-03-05 |
アムジエン・インコーポレーテツド |
組換えタンパク質の精製方法
|
|
WO2022191971A1
(en)
|
2021-03-10 |
2022-09-15 |
Amgen Inc. |
Parallel chromatography systems and methods
|
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
EP4314075A4
(en)
*
|
2021-03-24 |
2025-04-09 |
Twist Bioscience Corporation |
VARIANT NUCLEIC ACID BANKS FOR CD3
|
|
US20250282887A1
(en)
|
2021-04-02 |
2025-09-11 |
Amgen Inc. |
Mageb2 binding constructs
|
|
US20240209080A1
(en)
*
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
WO2022233956A1
(en)
|
2021-05-05 |
2022-11-10 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding prame
|
|
JP2024518369A
(ja)
|
2021-05-06 |
2024-05-01 |
アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング |
増殖性疾患で使用されるｃｄ２０及びｃｄ２２標的化抗原結合分子
|
|
US20230190806A1
(en)
|
2021-10-06 |
2023-06-22 |
Immatics Biotechnologies Gmbh |
Methods of treating metastatic lesions and compositions thereof
|
|
JP2025500732A
(ja)
|
2021-10-27 |
2025-01-15 |
アムジエン・インコーポレーテツド |
分光法を使用して薬剤を監視するための深層学習ベースの予測
|
|
IL312515A
(en)
|
2021-11-03 |
2024-07-01 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
US20260070986A1
(en)
|
2021-11-03 |
2026-03-12 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
EP4448108A1
(en)
|
2021-11-08 |
2024-10-23 |
Immatics Biotechnologies GmbH |
Adoptive cell therapy combination treatment and compositions thereof
|
|
TW202342097A
(zh)
|
2022-02-25 |
2023-11-01 |
學校法人順天堂 |
抗突變calr抗體與其他藥劑組合而成之醫藥
|
|
US20250354995A1
(en)
|
2022-04-29 |
2025-11-20 |
Immatics Biotechnologies Gmbh |
Mammalian display platform for multispecific antigen binding proteins
|
|
EP4522651A1
(en)
|
2022-05-12 |
2025-03-19 |
Amgen Research (Munich) GmbH |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
CN119948053A
(zh)
*
|
2022-06-30 |
2025-05-06 |
摩德斯医疗股份有限公司 |
抗SARS-CoV-2抗原结合多肽、多肽复合物及其使用方法
|
|
TW202421650A
(zh)
|
2022-09-14 |
2024-06-01 |
美商安進公司 |
雙特異性分子穩定組成物
|
|
EP4598958A1
(en)
|
2022-10-05 |
2025-08-13 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
KR20250157375A
(ko)
|
2023-03-08 |
2025-11-04 |
암젠 인크 |
이중특이적 분자에 대한 제어된 빙핵 형성 동결건조 공정
|
|
UY40797A
(es)
|
2023-06-14 |
2024-12-31 |
Amgen Inc |
Moléculas captadoras de enmascaramiento de células t
|
|
CN121358777A
(zh)
|
2023-07-27 |
2026-01-16 |
伊玛提克斯生物技术有限公司 |
抗mageb2的抗原结合蛋白
|
|
KR20260049657A
(ko)
|
2023-08-22 |
2026-04-14 |
암젠 인크 |
의약품의 효율적인 포장 방법 및 어셈블리
|
|
WO2025101672A1
(en)
|
2023-11-06 |
2025-05-15 |
City Of Hope |
Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
|
|
WO2025226901A1
(en)
|
2024-04-25 |
2025-10-30 |
Amgen Inc. |
Pairing of two-chain constructs
|
|
WO2025233432A1
(en)
|
2024-05-07 |
2025-11-13 |
Immatics Biotechnologies Gmbh |
Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide
|
|
WO2025257588A1
(en)
|
2024-06-10 |
2025-12-18 |
Affimed Gmbh |
Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
|
|
WO2025259515A2
(en)
|
2024-06-11 |
2025-12-18 |
Amgen Inc. |
Combination treatment
|
|
WO2026025031A1
(en)
|
2024-07-26 |
2026-01-29 |
Modernatx, Inc. |
Mrna encoding mageb2 tcer molecule
|
|
WO2026072671A1
(en)
|
2024-09-24 |
2026-04-02 |
City Of Hope |
Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies
|
|
WO2026082746A1
(en)
|
2024-10-14 |
2026-04-23 |
Immatics Biotechnologies Gmbh |
Bispecific molecule formulation
|